Aryx Therapeutics OTC Stock Buy Hold or Sell Recommendation


USD 0.0005  0.00  0.00%   

Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Aryx Therapeutics is 'Strong Sell'. Macroaxis provides Aryx Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ARYX positions. The advice algorithm takes into account all of Aryx Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
The advice is provided from Aryx Therapeutics' buy-and-hold perspective. Please continue to Aryx Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. We conduct extensive research on individual companies such as Aryx Therapeutics and provide practical buy, sell, or hold advice based on selected investing horizon and risk tolerance towards Aryx Therapeutics.

Execute Aryx Therapeutics Buy or Sell Advice

The Aryx Therapeutics recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Aryx Therapeutics. Macroaxis does not own or have any residual interests in Aryx Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Aryx Therapeutics' advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Aryx TherapeuticsBuy Aryx Therapeutics
Strong Sell



Hype Condition


Current Valuation


Odds of Distress


Economic Sensitivity


Analyst Consensus

Not Available

Reporting Quality (M-Score)

For the selected time horizon Aryx Therapeutics has a Mean Deviation of 0.7461, Standard Deviation of 3.08 and Variance of 9.47
We provide trade advice to complement the prevailing expert consensus on Aryx Therapeutics. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Aryx Therapeutics is not overpriced, please confirm all Aryx Therapeutics fundamentals, including its current ratio, as well as the relationship between the beta and current liabilities . As Aryx Therapeutics appears to be a penny stock we also recommend to validate its price to sales numbers.

Aryx Therapeutics Trading Alerts and Improvement Suggestions

Aryx Therapeutics generated a negative expected return over the last 90 days
Aryx Therapeutics has some characteristics of a very speculative penny stock
Aryx Therapeutics has a very high chance of going through financial distress in the upcoming years
The company currently holds 11.57 M in liabilities. Aryx Therapeutics has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aryx Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Aryx Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aryx Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aryx Therapeutics to invest in growth at high rates of return. When we think about Aryx Therapeutics' use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 19.72 M. Net Loss for the year was (18.33 M) with profit before overhead, payroll, taxes, and interest of 0.
Aryx Therapeutics currently holds about 2.95 M in cash with (20.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Aryx Therapeutics Returns Distribution Density

The distribution of Aryx Therapeutics' historical returns is an attempt to chart the uncertainty of Aryx Therapeutics' future price movements. The chart of the probability distribution of Aryx Therapeutics stock daily returns describes the distribution of returns around its average expected value. We use Aryx Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Aryx Therapeutics returns is essential to provide solid investment advice for Aryx Therapeutics.
Mean Return0.38Value At Risk0.00
Potential Upside0.00Standard Deviation3.08
   Return Density   
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Aryx Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Aryx Therapeutics Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Aryx Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Aryx Therapeutics' price will be affected by overall otc stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Aryx Therapeutics otc's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
Alpha over DOW
Beta against DOW0.80
Overall volatility
Information ratio 0.14

Aryx Therapeutics Volatility Alert

Aryx Therapeutics exhibits very low volatility with skewness of 8.12 and kurtosis of 66.0. However, we advise investors to further study Aryx Therapeutics technical indicators to ensure that all market info is available and is reliable. Aryx Therapeutics appears to be a penny stock. Although Aryx Therapeutics may be, in fact, a solid short-term or long term investment, many penny otc stocks are speculative investment instruments that are often subject to artificial stock promotion and campaigns of hype which may lead to misinformation and misrepresentation. Please make sure you fully understand upside potential and downside risks of investing in Aryx Therapeutics or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswing without any event/news,and sudden news releases. We also encourage traders to check biographies and work history of company President, CEO or other officers before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Aryx Therapeutics instrument if you perfectly time your entry and exit. However, remember that penny otcs that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Aryx Therapeutics Fundamentals Vs Peers

Comparing Aryx Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Aryx Therapeutics' direct or indirect competition across all of the common fundamentals between Aryx Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Aryx Therapeutics or determine the otc stocks which would be an excellent addition to an existing portfolio. Peer analysis of Aryx Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Aryx Therapeutics by comparing valuation metrics with those of similar companies.
 Better Than Average     
 Worse Than Average Compare Aryx Therapeutics to competition
FundamentalsAryx TherapeuticsPeer Average
Return On Equity(13,243) %(0.31) %
Return On Asset(74.86) %(0.14) %
Current Valuation8.64 M16.62 B
Shares Outstanding33.46 M571.82 M
Shares Owned by Institutions0.15 %39.21 %
Number of Shares Shorted89.05 K4.71 M
Price to Book(30.37) X9.51 X
Price to Sales2.79 X11.42 X
Revenue19.72 M9.43 B
EBITDA(14.18 M)3.9 B
Net Income(18.33 M)570.98 M
Cash and Equivalents2.95 M2.7 B
Cash per Share0.09 X5.01 X
Total Debt11.57 M5.32 B
Debt to Equity(5.11) %48.70 %
Current Ratio0.47 X2.16 X
Book Value Per Share(0.23) X1.93 K
Cash Flow from Operations(20.07 M)971.22 M
Short Ratio0.79 X4.00 X
Earnings Per Share(0.59) X3.12 X
Number of Employees5618.84 K
Market Capitalization51.65 K19.03 B
Total Asset11.97 M29.47 B
Retained Earnings(187.11 M)9.33 B
Working Capital126 K1.48 B
Current Asset8.62 M9.34 B
Current Liabilities8.49 M7.9 B
Z Score-23.38.72
   Acquisition by Druzgala Pascal of 35000 shares of Aryx Therapeutics subject to Rule 16b-3 [view details]

About Aryx Therapeutics Buy or Sell Advice

When is the right time to buy or sell Aryx Therapeutics? Buying financial instruments such as Aryx Therapeutics OTC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Aryx Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Junk Bonds Thematic Idea Now

Junk Bonds
Junk Bonds Theme
Funds or Etfs that invest most of their assets into speculative (junk) bonds or to other fixed income instruments with interest rates 3 to 4 percentage points above government issues. The Junk Bonds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Junk Bonds Theme or any other thematic opportunities.
View All  Next Launch
Please continue to Aryx Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for analysis

When running Aryx Therapeutics price analysis, check to measure Aryx Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aryx Therapeutics is operating at the current time. Most of Aryx Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aryx Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Aryx Therapeutics' price. Additionally, you may evaluate how the addition of Aryx Therapeutics to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Equity Valuation
Check real value of public entities based on technical and fundamental data
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Is Aryx Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aryx Therapeutics. If investors know Aryx Therapeutics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aryx Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aryx Therapeutics is measured differently than its book value, which is the value of Aryx Therapeutics that is recorded on the company's balance sheet. Investors also form their own opinion of Aryx Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aryx Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aryx Therapeutics' market value can be influenced by many factors that don't directly affect Aryx Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aryx Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Aryx Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aryx Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.